Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | APP | P05067 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12715186 | 0.92 | GAA (0.44) | GAAAPPTSHRALDH1A1MCL1 | |
| SCHEMBL12715139 | 0.83 | APP (0.43) | APP | |
| SCHEMBL13943136 | 0.82 | GAA (0.54) | GAAAPPTSHRALDH1A1MCL1 | |
| SCHEMBL12153959 | 0.82 | GAA (0.54) | GAAAPPTSHRALDH1A1MCL1 | |
| SCHEMBL12715212 | 0.80 | ALDH1A1 (0.35) | APPALDH1A1NPSR1KDM4EHPGD | |
| SCHEMBL12715127 | 0.80 | ALDH1A1 (0.35) | APPALDH1A1NPSR1KDM4EHPGD | |
| SCHEMBL13877535 | 0.79 | APP (0.34) | APP | |
| SCHEMBL13397808 | 0.79 | ALDH1A1 (0.36) | APPALDH1A1NPSR1KDM4EHPGD | |
| SCHEMBL12545104 | 0.79 | ALDH1A1 (0.36) | APPALDH1A1NPSR1KDM4EHPGD | |
| SCHEMBL12544909 | 0.79 | ALDH1A1 (0.36) | APPALDH1A1NPSR1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039630-B2 | Cationic compound, dye compound and method of using the same, and optical information recording medium | FUJIFILM CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| US-8039630-B2 | Cationic compound, dye compound and method of using the same, and optical information recording medium | FUJIFILM CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20090130367-A1 | CATIONIC COMPOUND, DYE COMPOUND AND METHOD OF USING THE SAME, AND OPTICAL INFORMATION RECORDING MEDIUM | FUJIFILM CORPORATION (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090130367-A1 | CATIONIC COMPOUND, DYE COMPOUND AND METHOD OF USING THE SAME, AND OPTICAL INFORMATION RECORDING MEDIUM | FUJIFILM CORPORATION (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090082570-A1 | METHOD OF MANUFACTURING BIPYRIDINIUM COMPOUND AND SYNTHETIC INTERMEDIATE OF THE SAME, METHOD OF MANUFACTURING DYE COMPOUND, AND NOVEL BIPYRIDINIUM COMPOUND AND NOVEL DYE COMPOUND COMPRISING THE SAME | FUJIFILM CORPORATION (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082570-A1 | METHOD OF MANUFACTURING BIPYRIDINIUM COMPOUND AND SYNTHETIC INTERMEDIATE OF THE SAME, METHOD OF MANUFACTURING DYE COMPOUND, AND NOVEL BIPYRIDINIUM COMPOUND AND NOVEL DYE COMPOUND COMPRISING THE SAME | FUJIFILM CORPORATION (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20080274423-A1 | OPTICAL INFORMATION RECORDING MEDIUM AND METHOD OF RECORDING INFORMATION | FUJIFILM CORPORATION (JP) | 2008-11-06 | — | — | US | disclosed |
| US-20080274423-A1 | OPTICAL INFORMATION RECORDING MEDIUM AND METHOD OF RECORDING INFORMATION | FUJIFILM CORPORATION (JP) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082570-A1 | METHOD OF MANUFACTURING BIPYRIDINIUM COMPOUND AND SYNTHETIC INTERMEDIATE OF THE SAME, METHOD OF MANUFACTURING DYE COMPOUND, AND NOVEL BIPYRIDINIUM COMPOUND AND NOVEL DYE COMPOUND COMPRISING THE SAME | RRS1, RPS3, ADRM1 | GAA 4429/4885APP 1961/4885TSHR 398/4885 |
| US-20090130367-A1 | CATIONIC COMPOUND, DYE COMPOUND AND METHOD OF USING THE SAME, AND OPTICAL INFORMATION RECORDING MEDIUM | CHRM1, CHRM2, TRPC6 | GAA 4416/4885APP 1245/4885TSHR 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.